Lipid Nanoparticle Formulations Capable of Migrating to Systemic Organs Following Intramuscular Administration

Value Proposition:

• Organ-targeted drug or mRNA delivery to focus therapy on specific tissues.
• Accessible intramuscular administration, offering broadly applicable, out-of-the-box drug delivery system for a range of therapeutics.
• Achieves organ-specific delivery without antibodies or targeting ligands, simplifying manufacturing and scalability.

Unmet Need

Targeting lipid nanoparticle drug delivery allows for more efficient delivery of nucleic acid therapies and reduction of off-target effects. Most current lipid nanoparticle delivery strategies for tissue targeting rely on intravenous or inhalation routes, which can be clinically impractical or inconvenient. There remains a critical need for LNP platforms that enable tissue-specific delivery through more accessible routes such as intramuscular injection.

Technology Description

Researchers at Johns Hopkins have developed a lipid nanoparticle formulation and a high-throughput screening platform to identify LNPs capable of trafficking to systemic organs following intramuscular administration. This approach enables precise characterization of organ-specific biodistribution—such as liver accumulation—after local injection. The platform is broadly adaptable for the delivery of various mRNA payloads or small-molecule therapeutics, offering a non-invasive and easy-to-administer strategy for tissue-specific drug delivery.

Stage of Development

• Researchers have finished proof-of-concept studies in mouse models.

Data Availability

• Data available upon request.

Publication

N/A